-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical network November 16 days ago, CDE official website shows that stone pharmaceutical group Europharma's hydrobrominate voxitin tablet imitation 4 categories of listing applications were accepted.
meters of intranet data show that in 2019, China's public medical institutions terminal voxel tablet sales of more than 30 million yuan, the first half of this year increased 190 percent year-on-year, only one production enterprises in Lingbei.
Prior to this, Yangzijiang Pharmaceuticals, Zhengda Tianqing Pharmaceutical Group, Jiangsu Haussen Pharmaceuticals, Chengdu Bett Pharmaceuticals and other five enterprises have submitted applications for listing, in the review and approval (in the drug review center).
data show that hydrobrominate vulcanization tablets are used to treat depression in adults.
November 2017, the hydrobrominate vulcanization tablets (commodity name Da Yue) developed by the Danish company Lingbei were approved for listing by the State Drug Administration.
In recent years, China's public medical institutions terminal vulcanization tablet sales (unit: 10,000 yuan) Source: China's public medical institutions terminal competition pattern Mienet data show that in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township health hospitals (referred to as China's public medical institutions) terminal voxelstatin tablet sales of more than 30 million yuan, the first half of this year increased by 190% year-on-year, production enterprises only Lingbei one.
source: MED2.0 China Drug Review Database Prior to this, Yangzijiang Pharmaceuticals, Zhengda Tianqing Pharmaceutical Group, Jiangsu Haussen Pharmaceuticals, Chengdu Bett Pharmaceuticals and other 5 enterprises have submitted applications for listing, in the review and approval (in the drug review center).
from the state start time, Yangzijiang pharmaceutical industry is the earliest.
source: CDE official website, Mienet database
